Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Costs and quality of life of patients with multiple sclerosis in Europe
- G. Kobelt, J. Berg, P. Lindgren, S. Fredrikson, B. Jönsson
- Medicine
- Journal of Neurology, Neurosurgery & Psychiatry
- 11 May 2006
Objective: To assess overall resource consumption, work capacity and quality of life of patients with multiple sclerosis in nine European countries. Methods: Information on resource consumption… Expand
Costs and quality of life in multiple sclerosis
- G. Kobelt, J. Berg, D. Atherly, O. Hadjimichael
- Medicine
- Neurology
- 4 October 2000
Objective: To estimate current costs and quality of life (utility) of patients treated with disease modifying drugs (DMDs) in the United States, and to investigate the effect of disease severity on… Expand
Costs and quality of life of multiple sclerosis in Spain
- G. Kobelt, J. Berg, +5 authors Associación Española de Esclerosis Múltiple
- Medicine
- The European Journal of Health Economics
- 2006
This cost-of-illness analysis is based on information from 1.848 patients in Spain and is part of a Europe-wide study on the costs of multiple sclerosis. The objective was to analyze the costs and… Expand
Costs and quality of life in multiple sclerosis
- G. Kobelt, P. Lindgren, +7 authors the German Cost of MS Study Group
- Medicine
- The European Journal of Health Economics (HEPAC)
- 1 June 2001
We performed a cross-sectional, “bottom-up” observational study of resource use, costs, and quality of life in patients with multiple sclerosis (MS) in Germany. Six centers participated in the study.… Expand
The burden of rheumatoid arthritis and access to treatment: health burden and costs
- J. Lundkvist, F. Kastäng, G. Kobelt
- Medicine
- The European Journal of Health Economics
- 2007
As part of the study “The burden of rheumatoid arthritis and patient access to treatment”, this paper reviews evidence on the health burden of rheumatoid arthritis (RA) in terms of morbidity (DALYs),… Expand
Costs and quality of life of multiple sclerosis in the United Kingdom
- G. Kobelt, J. Berg, P. Lindgren, J. Kerrigan, N. Russell, R. Nixon
- Medicine
- The European Journal of Health Economics
- 1 September 2006
This cost-of-illness analysis for the United Kingdom is part of a Europe-wide study on the costs of multiple sclerosis (MS). The objective was to analyze the costs and quality of life (utility)… Expand
Costs and quality of life of multiple sclerosis in Sweden
- J. Berg, P. Lindgren, S. Fredrikson, G. Kobelt
- Medicine
- The European Journal of Health Economics
- 1 September 2006
The study objective was to analyse the costs and quality of life (QOL) of multiple sclerosis (MS) related to disease severity in Sweden as part of a study in nine European countries. Information on… Expand
Costs and quality of life of multiple sclerosis in Italy
- G. Kobelt, J. Berg, P. Lindgren, M. Battaglia, C. Lucioni, A. Uccelli
- Medicine
- The European Journal of Health Economics
- 2006
This cost-of-illness analysis based on information from 921 patients in Italy is part of a Europe-wide cost-of-illness study in multiple sclerosis (MS). The objective was to analyze the costs and… Expand
Economic consequences of the progression of rheumatoid arthritis in Sweden.
- G. Kobelt, K. Eberhardt, L. Jönsson, B. Joensson
- Medicine
- Arthritis and rheumatism
- 1 February 1999
OBJECTIVE
To develop a simulation model for analysis of the cost-effectiveness of treatments that affect the progression of rheumatoid arthritis (RA).
METHODS
The Markov model was developed on the… Expand
TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
- G. Kobelt, K. Eberhardt, P. Geborek
- Medicine
- Annals of the rheumatic diseases
- 2004
OBJECTIVES
To evaluate costs, benefits, and cost effectiveness of tumour necrosis factor inhibitor treatment over one year in routine clinical practice.
MATERIALS AND METHODS
At four rheumatology… Expand